- Home
- NSTS vs ENTX Comparison
NSTS vs ENTX Comparison
Compare NSTS & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | ENTX |
|---|---|---|
| Founded | 1921 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 58.2M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NSTS | ENTX |
|---|---|---|
| Price | $13.75 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 13.0K | ★ 57.3K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $252,000.00 | $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.11 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.73 | $0.91 |
| 52 Week High | $13.82 | $3.22 |
Technical Indicators
Market Signals| Indicator | NSTS | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.66 | 48.48 |
| Support Level | $13.60 | $1.17 |
| Resistance Level | $13.75 | $1.37 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 44.41 | 22.73 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.